Amyotrophic Lateral Sclerosis (ALS)

NIH ALS Lithium Trial Stops

The investigators on a study of lithium carbonate in amyotrophic lateral sclerosis (ALS), funded by the National Institutes of Health, the ALS Association and the ALS Society of Canada, announced Sept. 23, 2009, that they will stop their study after an interim analysis showed the drug was not beneficial. MDA is not a funder of this study.

NIH Cuts Short ALS Lithium Trial; MDA’s Trial Continues for Now

The investigators on a study of lithium carbonate in amyotrophic lateral sclerosis (ALS), funded by the National Institutes of Health, the ALS Association and the ALS Society of Canada, announced Sept. 23, 2009, that they will stop their study after an interim analysis showed the drug was not beneficial. MDA is not a funder of this study.

First Human Stem Cell Trials for ALS to be Conducted at MDA/ALS Center in Atlanta

The first FDA-approved human stem cell trial to treat amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease will be conducted at the Muscular Dystrophy Association ALS Center at Emory University in Atlanta. 

The Food and Drug Administration has given Neuralstem, Inc., a Maryland biotherapeutics company, the go-ahead to conduct a Phase 1 trial to study the safety of Neuralstem’s cells and surgical procedures.

ALS Research: Risk Raisers

A large, multinational study to identify genetic risk factors associated with amyotrophic lateral sclerosis (ALS) has found two DNA sequences on chromosomes 9 and one on chromosome 19 that are significantly different in people with and without the disease and may contribute to its development.

ALS Research: Risk Raisers

A large, multinational study to identify genetic risk factors associated with amyotrophic lateral sclerosis (ALS) has found two DNA sequences on chromosomes 9 and one on chromosome 19 that are significantly different in people with and without the disease and may contribute to its development.

ALS Risk Raisers

A large, multinational study to identify genetic risk factors associated with amyotrophic lateral sclerosis (ALS) has found two DNA sequences on chromosomes 9 and one on chromosome 19 that are significantly different in people with and without the disease and may contribute to its development.

ALS Profile: Hawaiian Still Smiling

 

ALS Profile: Hawaiian Still Smiling

 

Untangling ALS

A new forum for easily accessible scientific information on alternative and off-label (not approved by the Food and Drug Administration) treatments for ALS is now being offered by the World Federation of Neurology (WFN) on its WFN ALS Web site. The forum, ALS Untangled (ALSU), uses Twitter for its communications.

Here's how it works:

ALS: Control for Laughing/Crying Outbursts

The pharamaceutical company Avanir has announced positive results for its phase 3 trial to treat unwanted episodes of laughing and crying in patients with ALS and multiple sclerosis using its experimental drug Zenvia.

Pages